Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
10 Jan 2022
10 Jan 2022
Historique:
received:
04
10
2021
accepted:
14
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection from SARS-CoV-2 infection and disease. In this study, we explored directly the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination by adoptive transfer studies. IgG from plasma of Ad26.COV2.S vaccinated individuals was purified and transferred into naïve golden Syrian hamster recipients, followed by intra-nasal challenge of the hamsters with SARS-CoV-2. IgG purified from Ad26.COV2.S-vaccinated individuals provided dose-dependent protection in the recipient hamsters from weight loss following challenge. In contrast, IgG purified from placebo recipients provided no protection in this adoptive transfer model. Attenuation of weight loss correlated with binding and neutralizing antibody titers of the passively transferred IgG. This study suggests that Ad26.COV2.S-elicited antibodies in humans are mechanistically involved in protection against SARS-CoV-2.
Identifiants
pubmed: 35013325
doi: 10.1038/s41541-021-00427-z
pii: 10.1038/s41541-021-00427-z
pmc: PMC8748674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007387
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260476
Pays : United States
Organisme : U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA)
ID : HHS0100201700018C
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : CA260476
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell. 2021 Jun 10;184(12):3086-3108
pubmed: 34087172
Cell. 2021 Jun 24;184(13):3467-3473.e11
pubmed: 34133941
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Ann Intern Med. 2021 May;174(5):585-594
pubmed: 33587687
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
Sci Immunol. 2021 Jul 1;6(61):
pubmed: 34210785
J Virol. 2021 Mar 16;:
pubmed: 33727331
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073
Nature. 2016 Aug 25;536(7617):474-8
pubmed: 27355570
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
NPJ Vaccines. 2021 Mar 19;6(1):39
pubmed: 33741993
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945